Autoantibodies in heart failure and cardiac dysfunction

Circulation Research

Volumn 110, Issue 1, 2012, Pages 145-158

  Kaya, Ziya ^a   Leib, Christoph ^a   Katus, Hugo A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

autoantibody; autoimmunity; heart failure; immunoadsorption; myocardial dysfunction

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AUTOANTIBODY; AUTOANTIGEN; BETA 1 ADRENERGIC RECEPTOR; CYTOKINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MITOCHONDRION ANTIBODY; MUSCARINIC M2 RECEPTOR; MYOSIN; PLACEBO; TROPONIN I;

B LYMPHOCYTE; DISEASE COURSE; HEART DISEASE; HEART FAILURE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOADSORPTION; INNATE IMMUNITY; MOLECULAR MECHANICS; MORBIDITY; MORTALITY; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; DISEASE PROGRESSION; HEART; HEART FAILURE; HUMANS; IMMUNITY, HUMORAL; MODELS, ANIMAL; MYOCARDIUM;

EID: 84855371938     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.111.243360     Document Type: Review

References (138)

1. Caforio AL, Mahon NG, Baig MK, Tona F, Murphy RT, Elliott PM, McKenna WJ. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation. 2007;1:76-83. (Pubitemid 46058614)
2. Felix SB, Staudt A. Non-specific immunoadsorption in patients with dilated cardiomyopathy: mechanisms and clinical effects. Int J Cardiol. 2006;1:30-33. (Pubitemid 44247196)
3. Doesch AO, Mueller S, Nelles M, Konstandin M, Celik S, Frankenstein L, Goeser S, Kaya Z, Koch A, Zugck C, Katus HA. Impact of troponin I-autoantibodies in chronic dilated and ischemic cardiomyopathy. Basic Res Cardiol. 2011;1:25-35.
4. Germain RN. T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol. 2002;5:309-322. (Pubitemid 37328754)
5. Fleming SD, Tsokos GC. Complement, natural antibodies, autoantibodies and tissue injury. Autoimmun Rev. 2006;2:89-92. (Pubitemid 43136464)
6. Nielsen CH, Hegedus L, Leslie RG. Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. Eur J Immunol. 2004;1:263-272. (Pubitemid 38111542)
7. Norsworthy P, Davies KA. Complement components and their autoantibodies. Mol Biotechnol. 2003;3:259-270. (Pubitemid 36308439)
8. Wallukat G, Munoz Saravia SG, Haberland A, Bartel S, Araujo R, Valda G, Duchen D, Diaz R, I, Borges AC, Schimke I. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas' cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas' patients. J Am Coll Cardiol. 2010; 5:463-468.
9. Yu X, Patterson E, Stavrakis S, Huang S, De AI, Hamlett S, Cunningham MW, Lazarra R, Kem DC. Development of cardiomyopathy and atrial tachyarrhythmias associated with activating autoantibodies to beta-adrenergic and muscarinic receptors. J Am Soc Hypertens. 2009;2: 133-140.
10. Balazs C, Farid NR. MHC class II expression in Graves' disease. Thyroid. 2002;2:181-182. (Pubitemid 34214006)
11. Iwasa K, Kato-Motozaki Y, Furukawa Y, Maruta T, Ishida C, Yoshikawa H, Yamada M. Up-regulation of MHC class I and class II in the skeletal muscles of myasthenia gravis. J Neuroimmunol. 2010;1-2: 171-174.
12. Kroner A, Grimm A, Johannssen K, Maurer M, Wiendl H. The genetic influence of the nonclassical MHC molecule HLA-G on multiple sclerosis. Hum Immunol. 2007;5:422-425. (Pubitemid 46616980)
13. Newton JL, Harney SM, Wordsworth BP, Brown MA. A review of the MHC genetics of rheumatoid arthritis. Genes Immun. 2004;3:151-157. (Pubitemid 38967646)
14. Raddassi K, Kent SC, Yang J, Bourcier K, Bradshaw EM, Seyfert-Margolis V, Nepom GT, Kwok WW, Hafler DA. Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis. J Immunol. 2011;2:1039-1046.
15. Leuschner F, Katus HA, Kaya Z. Autoimmune myocarditis: past, present and future. J Autoimmun. 2009;3-4:282-289.
16. Jahns R, Boivin V, Schwarzbach V, Ertl G, Lohse MJ. Pathological autoantibodies in cardiomyopathy. Autoimmunity. 2008;6:454-461.
17. Levin MJ, Hoebeke J. Cross-talk between anti-beta1-adrenoceptor antibodies in dilated cardiomyopathy and Chagas' heart disease. Autoimmunity. 2008;6:429-433.
18. Liang CS, Mao W, Liu J. Pro-apoptotic effects of anti-beta1-adrenergic receptor antibodies in cultured rat cardiomyocytes: actions on endoplasmic reticulum and the prosurvival PI3K-Akt pathway. Autoimmunity. 2008;6: 434-441.
19. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by antineutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;1:52-64. (Pubitemid 47339189)
20. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011;9:1133-1145.
21. Crampton SP, Voynova E, Bolland S. Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci. 2010;1183:58-68.
22. Blyszczuk P, Kania G, Dieterle T, Marty RR, Valaperti A, Berthonneche C, Pedrazzini T, Berger CT, Dirnhofer S, Matter CM, Penninger JM, Luscher TF, Eriksson U. Myeloid differentiation factor-88/interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. Circ Res. 2009;9:912-920.
23. Riad A, Westermann D, Escher F, Becher PM, Savvatis K, Lettau O, Heimesaat MM, Bereswill S, Volk HD, Schultheiss HP, Tschope C. Myeloid differentiation factor-88 contributes to TLR9-mediated modulation of acute coxsackievirus B3-induced myocarditis in vivo. Am J Physiol Heart Circ Physiol. 2010;6:H2024-H2031.
24. Pagni PP, Traub S, Demaria O, Chasson L, Alexopoulou L. Contribution of TLR7 and TLR9 signaling to the susceptibility of MyD88-deficient mice to myocarditis. Autoimmunity. 2010;4:275-287.
25. Birks EJ, Felkin LE, Banner NR, Khaghani A, Barton PJ, Yacoub MH. Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant. 2004;2: 228-235. (Pubitemid 38175301)
26. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;3:271-280.
27. Fairweather D, Frisancho-Kiss S, Njoku DB, Nyland JF, Kaya Z, Yusung SA, Davis SE, Frisancho JA, Barrett MA, Rose NR. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart. J Immunol. 2006;6:3516-3524. (Pubitemid 43363999)
28. Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T, Fairweather D, Holers VM, Rose NR. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol. 2001;8:739-745. (Pubitemid 32747164)
29. Zimmermann O, Kochs M, Zwaka TP, Bienek-Ziolkowski M, Hoher M, Hombach V, Torzewski J. Prognostic role of myocardial tumor necrosis factor-alpha and terminal complement complex expression in patients with dilated cardiomyopathy. Eur J Heart Fail. 2007;1:51-54. (Pubitemid 46084958)
30. Wallukat G. The beta-adrenergic receptors. Herz. 2002;7:683-690.
31. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against betaadrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res. 1989;1:97-103. (Pubitemid 19028507)
32. Magnusson Y, Marullo S, Hoyer S, Waagstein F, Andersson B, Vahlne A, Guillet JG, Strosberg AD, Hjalmarson A, Hoebeke J. Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1990;5: 1658-1663. (Pubitemid 20372617)
33. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation. 1994;6:2760-2767. (Pubitemid 24173697)
34. Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, Wainai Y, Takahashi T, Ogawa S. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res. 2001;6: 578-586. (Pubitemid 32275793)
35. Liu HR, Zhao RR, Jiao XY, Wang YY, Fu M. Relationship of myocardial remodeling to the genesis of serum autoantibodies to cardiac beta(1)-adrenoceptors and muscarinic type 2 acetylcholine receptors in rats. J Am Coll Cardiol. 2002;11:1866-1873. (Pubitemid 34595301)
36. Di LA, Remme WJ, Charlesworth A, Cleland JG, Lutiger B, Metra M, Komajda M, Torp-Pedersen C, Scherhag A, Swedberg K, Poole-Wilson PA. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur J Heart Fail. 2005;4:640-649. (Pubitemid 40732998)
37. Greenberg B. Nonselective versus selective beta-blockers in the management of chronic heart failure: clinical implications of the carvedilol or Metoprolol European Trial. Rev Cardiovasc Med. 2004;5:S10-S17. (Pubitemid 38811475)
38. Jahns R, Schlipp A, Boivin V, Lohse MJ. Targeting receptor antibodies in immune cardiomyopathy. Semin Thromb Hemost. 2010;2:212-218.
39. Nagatomo Y, Yoshikawa T, Kohno T, Yoshizawa A, Baba A, Anzai T, Meguro T, Satoh T, Ogawa S. A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. J Card Fail. 2009;3:224-232.
40. Deubner N, Berliner D, Schlipp A, Gelbrich G, Caforio AL, Felix SB, Fu M, Katus H, Angermann CE, Lohse MJ, Ertl G, Stork S, Jahns R. Cardiac beta1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study. Eur J Heart Fail. 2010;7:753-762.
41. Nikolaev VO, Boivin V, Stork S, Angermann CE, Ertl G, Lohse MJ, Jahns R. A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol. 2007;5:423-431. (Pubitemid 47088126)
42. Fu LX, Magnusson Y, Bergh CH, Liljeqvist JA, Waagstein F, Hjalmarson A, Hoebeke J. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1993;5:1964-1968. (Pubitemid 23141466)
43. Fu ML, Hoebeke J, Matsui S, Matoba M, Magnusson Y, Hedner T, Herlitz H, Hjalmarson A. Autoantibodies against cardiac G-proteincoupled receptors define different populations with cardiomyopathies but not with hypertension. Clin Immunol Immunopathol. 1994;1:15-20. (Pubitemid 24227331)
44. Matsui S, Fu ML, Shimizu M, Fukuoka T, Teraoka K, Takekoshi N, Murakami E, Hjalmarson A. Dilated cardiomyopathy defines serum autoantibodies against G-protein-coupled cardiovascular receptors. Autoimmunity. 1995;2:85-88. (Pubitemid 26011165)
45. Fu ML. Anti-peptide antibodies against an autoimmune epitope on human muscarinic receptor mimic functional autoantibodies against the same epitope in patients with idiopathic dilated cardiomyopathy. Eur Heart J. 1995;16:89-91. (Pubitemid 26082354)
46. Wang WZ, Zhao RR, Wu BW, Jin XH, Zhu L, Hjalmarson A, Fu ML. Effects of anti-peptide antibodies against human M2 muscarinic receptors on cardiac function in rats in vivo. Blood Press Suppl. 1996; 3:25-27. (Pubitemid 26402711)
47. Matsui S, Fu ML, Katsuda S, Hayase M, Yamaguchi N, Teraoka K, Kurihara T, Takekoshi N, Murakami E, Hoebeke J, Hjalmarson A. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol. 1997;2:641-655. (Pubitemid 27192871)
48. Stavrakis S, Kem DC, Patterson E, Lozano P, Huang S, Szabo B, Cunningham MW, Lazzara R, Yu X. Opposing cardiac effects of autoantibody activation of beta-adrenergic and M2 muscarinic receptors in cardiac-related diseases. Int J Cardiol. 2011;3:331-336.
49. Berg PA, Klein R. Mitochondrial antigens and autoantibodies: from anti-M1 to anti-M9. Klin Wochenschr. 1986;19:897-909. (Pubitemid 16032242)
50. Klein R, Maisch B, Kochsiek K, Berg PA. Demonstration of organ specific antibodies against heart mitochondria (anti-M7) in sera from patients with some forms of heart diseases. Clin Exp Immunol. 1984;2: 283-292. (Pubitemid 15201847)
51. Bottazzo GF, Todd I, Mirakian R, Belfiore A, Pujol-Borrell R. Organspecific autoimmunity: a 1986 overview. Immunol Rev. 1986;94:137-169.
52. Schultheiss HP, Schwimmbeck P, Bolte HD, Klingenberg M. The antigenic characteristics and the significance of the adenine nucleotide translocator as a major autoantigen to antimitochondrial antibodies in dilated cardiomyopathy. Adv Myocardiol. 1985;6:311-327.
53. Schultheiss HP, Bolte HD. Immunological analysis of auto-antibodies against the adenine nucleotide translocator in dilated cardiomyopathy. J Mol Cell Cardiol. 1985;17:603-617. (Pubitemid 15064000)
54. Manchado C, Orus J, Villarroya F, Roig E, Heras M, Giralt M, Iglesias R, Sanz G, Mampel T, Vinas O. Epitope mapping of mitochondrial adenine nucleotide translocase-1 in idiopathic dilated cardiomyopathy. J Mol Cell Cardiol. 2002;5:571-582.
55. Schwimmbeck PL, Schwimmbeck NK, Schultheiss HP, Strauer BE. Mapping of antigenic determinants of the adenine-nucleotide translocator and coxsackie B3 virus with synthetic peptides: use for the diagnosis of viral heart disease. Clin Immunol Immunopathol. 1993;2: 135-140. (Pubitemid 23278064)
56. Andreoletti L, Leveque N, Boulagnon C, Brasselet C, Fornes P. Viral causes of human myocarditis. Arch Cardiovasc Dis. 2009;6-7:559-568.
57. Schulze K, Witzenbichler B, Christmann C, Schultheiss HP. Disturbance of myocardial energy metabolism in experimental virus myocarditis by antibodies against the adenine nucleotide translocator. Cardiovasc Res. 1999;1:91-100. (Pubitemid 29431687)
58. Schulze K, Heineman FW, Schultheiss HP, Balaban RS. Impairment of myocardial calcium homeostasis by antibodies against the adenine nucleotide translocator. Cell Calcium. 1999;5:361-370. (Pubitemid 29374039)
59. Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, Gabrielson K, Iwakura Y, Rose NR, Cihakova D. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res. 2010;10:1646-1655.
60. Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH, Wang JP, Zhang JH, Wang M, Guo HP, Liao YH. Neutralization of IL-17 inhibits the production of anti-ANT autoantibodies in CVB3-induced acute viral myocarditis. Int Immunopharmacol. 2010;3:272-276.
61. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol. 1987;11:3630-3636. (Pubitemid 18013633)
62. Mercadier JJ, Bouveret P, Gorza L, Schiaffino S, Clark WA, Zak R, Swynghedauw B, Schwartz K. Myosin isoenzymes in normal and hypertrophied human ventricular myocardium. Circ Res. 1983;1:52-62. (Pubitemid 13031768)
63. Caforio AL, Grazzini M, Mann JM, Keeling PJ, Bottazzo GF, McKenna WJ, Schiaffino S. Identification of alpha-and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992;5:1734-1742.
64. Lauer B, Padberg K, Schultheiss HP, Strauer BE. Autoantibodies against human ventricular myosin in sera of patients with acute and chronic myocarditis. J Am Coll Cardiol. 1994;1:146-153. (Pubitemid 24027203)
65. Neumann DA, Rose NR, Ansari AA, Herskowitz A. Induction of multiple heart autoantibodies in mice with coxsackievirus B3-and cardiac myosin-induced autoimmune myocarditis. J Immunol. 1994;1: 343-350.
66. Warraich RS, Noutsias M, Kazak I, Seeberg B, Dunn MJ, Schultheiss HP, Yacoub MH, Kuhl U. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J. 2002;6:1076-1084. (Pubitemid 34666901)
67. Warraich RS, Griffiths E, Falconar A, Pabbathi V, Bell C, Angelini G, Suleiman MS, Yacoub MH. Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship. FASEB J. 2006;6:651-660. (Pubitemid 44933309)
68. Kuan AP, Chamberlain W, Malkiel S, Lieu HD, Factor SM, Diamond B, Kotzin BL. Genetic control of autoimmune myocarditis mediated by myosin-specific antibodies. Immunogenetics. 1999;2:79-85. (Pubitemid 29037595)
69. Kuan AP, Zuckier L, Liao L, Factor SM, Diamond B. Immunoglobulin isotype determines pathogenicity in antibody-mediated myocarditis in naive mice. Circ Res. 2000;3:281-285. (Pubitemid 30108821)
70. Liao L, Sindhwani R, Rojkind M, Factor S, Leinwand L, Diamond B. Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med. 1995;3:1123-1131.
71. Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol. 2006;11:8234-8240. (Pubitemid 44846345)
72. Freedman NJ, Lefkowitz RJ. Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest. 2004;10:1379-1382. (Pubitemid 39071690)
73. Saito S, Hiroi Y, Zou Y, Aikawa R, Toko H, Shibasaki F, Yazaki Y, Nagai R, Komuro I. beta-Adrenergic pathway induces apoptosis through calcineurin activation in cardiac myocytes. J Biol Chem. 2000;44: 34528-34533.
74. Lv H, Havari E, Pinto S, Gottumukkala RV, Cornivelli L, Raddassi K, Matsui T, Rosenzweig A, Bronson RT, Smith R, Fletcher AL, Turley SJ, Wucherpfennig K, Kyewski B, Lipes MA. Impaired thymic tolerance to alpha-myosin directs autoimmunity to the heart in mice and humans. J Clin Invest. 2011;4:1561-1573.
75. Klein L, Hinterberger M, Wirnsberger G, Kyewski B. Antigen presentation in the thymus for positive selection and central tolerance induction. Nat Rev Immunol. 2009;12:833-844.
76. Morita H, Seidman J, Seidman CE. Genetic causes of human heart failure. J Clin Invest. 2005;3:518-526. (Pubitemid 40322221)
77. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 5502:319-322. (Pubitemid 32096320)
78. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;12:1477-1483. (Pubitemid 38004774)
79. Goser S, Andrassy M, Buss SJ, Leuschner F, Volz CH, Ottl R, Zittrich S, Blaudeck N, Hardt SE, Pfitzer G, Rose NR, Katus HA, Kaya Z. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation. 2006;16: 1693-1702. (Pubitemid 44607117)
80. Latva-Hirvela J, Kyto V, Saraste A, Eriksson S, Vuorinen T, Pettersson K, Saukko P. Development of troponin autoantibodies in experimental coxsackievirus B3 myocarditis. Eur J Clin Invest. 2009;6:457-462.
81. Kaya Z, Goser S, Buss SJ, Leuschner F, Ottl R, Li J, Volkers M, Zittrich S, Pfitzer G, Rose NR, Katus HA. Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis. Circulation. 2008;20:2063-2072.
82. Leuschner F, Li J, Goser S, Reinhardt L, Ottl R, Bride P, Zehelein J, Pfitzer G, Remppis A, Giannitsis E, Katus HA, Kaya Z. Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction. Eur Heart J. 2008;16:1949-1955.
83. Miettinen KH, Eriksson S, Magga J, Tuomainen P, Kuusisto J, Vanninen EJ, Turpeinen A, Punnonen KR, Pettersson K, Peuhkurinen KJ. Clinical significance of troponin I efflux and troponin autoantibodies in patients with dilated cardiomyopathy. J Card Fail. 2008;6:481-488. (Pubitemid 352040862)
84. Halley CM, Lappe JM, Cotleur AC, Shrestha K, Borowski AG, Pelfrey C, Ransohoff R, Tang WH. Antiinflammatory autoimmune cellular responses to cardiac troponin I in idiopathic dilated cardiomyopathy. J Card Fail. 2011;5:359-365.
85. Norgaard A, Bagger JP, Bjerregaard P, Baandrup U, Kjeldsen K, Thomsen PE. Relation of left ventricular function and Na,K-pump concentration in suspected idiopathic dilated cardiomyopathy. Am J Cardiol. 1988;15:1312-1315.
86. Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2002;6:1153-1159.
87. Baba A, Yoshikawa T, Iwata M, Anzai T, Nakamura I, Wainai Y, Ogawa S, Fu M. Antigen-specific effects of autoantibodies against sarcolemmal Na-K-ATPase pump in immunized cardiomyopathic rabbits. Int J Cardiol. 2006;1:15-20. (Pubitemid 44262405)
88. Latif N, Smith J, Dunn MJ, Yacoub MH, Rose ML. Complementmediated cytotoxic activity of anti-heart antibodies present in the sera of patients with dilated cardiomyopathy. Autoimmunity. 1994;2:99-104.
89. Winrow VR, McLean L, Morris CJ, Blake DR. The heat shock protein response and its role in inflammatory disease. Ann Rheum Dis. 1990;2: 128-132. (Pubitemid 20041019)
90. Latif N, Baker CS, Dunn MJ, Rose ML, Brady P, Yacoub MH. Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting. J Am Coll Cardiol. 1993;5:1378-1384. (Pubitemid 23316362)
91. Latif N, Zhang H, Archard LC, Yacoub MH, Dunn MJ. Characterization of anti-heart antibodies in mice after infection with coxsackie B3 virus. Clin Immunol. 1999;1:90-98.
92. Lin L, Kim SC, Wang Y, Gupta S, Davis B, Simon SI, Torre-Amione G, Knowlton AA. HSP60 in heart failure: abnormal distribution and role in cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol. 2007;4: H2238-H2247. (Pubitemid 47605867)
93. Ansari AA, Wang YC, Danner DJ, Gravanis MB, Mayne A, Neckelmann N, Sell KW, Herskowitz A. Abnormal expression of histocompatibility and mitochondrial antigens by cardiac tissue from patients with myocarditis and dilated cardiomyopathy. Am J Pathol. 1991;2: 337-354.
94. Goin JC, Borda ES, Auger S, Storino R, Sterin-Borda L. Cardiac M(2) muscarinic cholinoceptor activation by human chagasic autoantibodies: association with bradycardia. Heart. 1999;3:273-278. (Pubitemid 29429596)
95. Kamel R, Eftekhari P, Clancy R, Buyon JP, Hoebeke J. Autoantibodies against the serotoninergic 5-HT4 receptor and congenital heart block: a reassessment. J Autoimmun. 2005;1:72-76. (Pubitemid 41008668)
96. Khaw BA, Narula J, Sharaf AR, Nicol PD, Southern JF, Carles M. SR-Ca2+ ATPase as an autoimmunogen in experimental myocarditis. Eur Heart J. 1995;16:92-96. (Pubitemid 26082355)
97. Maisch B. Autoreactivity to the cardiac myocyte, connective tissue and the extracellular matrix in heart disease and postcardiac injury. Springer Semin Immunopathol. 1989;4:369-395. (Pubitemid 20014437)
98. Maisch B, Bauer E, Cirsi M, Kochsiek K. Cytolytic cross-reactive antibodies directed against the cardiac membrane and viral proteins in coxsackievirus B3 and B4 myocarditis. Characterization and pathogenetic relevance. Circulation. 1993;5(Suppl):IV49-IV65. (Pubitemid 23135650)
99. Maisch B, Ristic AD, Portig I, Pankuweit S. Human viral cardiomyopathy. Front Biosci. 2003;8:S39-S67. (Pubitemid 38930838)
100. Pankuweit S, Lottspeich F, Maisch B. Characterization of relevant membrane antigens by two-dimensional immunoblot and n-terminal sequence analysis in patients with myocarditis. Eur Heart J. 1995;16: 81-84. (Pubitemid 26082352)
101. Pankuweit S, Portig I, Lottspeich F, Maisch B. Autoantibodies in sera of patients with myocarditis: characterization of the corresponding proteins by isoelectric focusing and N-terminal sequence analysis. J Mol Cell Cardiol. 1997;1:77-84. (Pubitemid 27129132)
102. Pohlner K, Portig I, Pankuweit S, Lottspeich F, Maisch B. Identification of mitochondrial antigens recognized by antibodies in sera of patients with idiopathic dilated cardiomyopathy by two-dimensional gel electrophoresis and protein sequencing. Am J Cardiol. 1997;8:1040-1045. (Pubitemid 27459205)
103. Wolff PG, Kuhl U, Schultheiss HP. Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. Am Heart J. 1989;6:1303-1309. (Pubitemid 19150761)
104. Cooper LT, Belohlavek M, Korinek J, Yoshifuku S, Sengupta PP, Burgstaler EA, Winters JL. A pilot study to assess the use of protein a immunoadsorption for chronic dilated cardiomyopathy. J Clin Apher. 2007;4:210-214. (Pubitemid 47320235)
105. Ikeda U, Kasai H, Izawa A, Koyama J, Yazaki Y, Takahashi M, Higuchi M, Koh CS, Yamamoto K. Immunoadsorption therapy for patients with dilated cardiomyopathy and heart failure. Curr Cardiol Rev. 2008;3: 219-222.
106. Knebel F, Bohm M, Staudt A, Borges AC, Tepper M, Jochmann N, Wernicke KD, Felix S, Baumann G. Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy. Int J Cardiol. 2004;3:517-520. (Pubitemid 39550704)
107. Staudt A, Hummel A, Ruppert J, Dorr M, Trimpert C, Birkenmeier K, Krieg T, Staudt Y, Felix SB. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J. 2006;4: 712-716.
108. Wallukat G, Reinke P, Dorffel WV, Luther HP, Bestvater K, Felix SB, Baumann G. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol. 1996;2:191-195. (Pubitemid 26188306)
109. Dorffel WV, Wallukat G, Baumann G, Felix SB. Immunoadsorption in dilated cardiomyopathy. Ther Apher. 2000;3:235-238. (Pubitemid 30445878)
110. Felix SB, Staudt A, Dorffel WV, Stangl V, Merkel K, Pohl M, Docke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol. 2000; 6:1590-1598. (Pubitemid 30307505)
111. Staudt A, Schaper F, Stangl V, Plagemann A, Bohm M, Merkel K, Wallukat G, Wernecke KD, Stangl K, Baumann G, Felix SB. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation. 2001;22:2681-2686. (Pubitemid 32538782)
112. Anderson JL, Carlquist JF, Lutz JR, DeWitt CW, Hammond EH. HLA A, B and DR typing in idiopathic dilated cardiomyopathy: a search for immune response factors. Am J Cardiol. 1984;9:1326-1330. (Pubitemid 14118876)
113. Harcombe AA, Sharples L, Large SR, Wallwork J, Weissberg PL, Joysey V. HLA antigen frequencies in end-stage idiopathic and ischaemic cardiomyopathy. Int J Cardiol. 1999;1:31-37. (Pubitemid 29083363)
114. Mobini R, Staudt A, Felix SB, Baumann G, Wallukat G, Deinum J, Svensson H, Hjalmarson A, Fu M. Hemodynamic improvement and removal of autoantibodies against beta1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun. 2003;4: 345-350. (Pubitemid 36677526)
115. Kallwellis-Opara A, Staudt A, Trimpert C, Noutsias M, Kuhl U, Pauschinger M, Schultheiss HP, Grube M, Bohm M, Baumann G, Volker U, Kroemer HK, Felix SB. Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy. J Mol Med. 2007;12:1429-1435. (Pubitemid 350234098)
116. Bulut D, Scheeler M, Niedballa LM, Miebach T, Mugge A. Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy. Clin Res Cardiol. 2011;100:603-610.
117. Orozco AF, Lewis DE. Flow cytometric analysis of circulating microparticles in plasma. Cytometry A. 2010;6:502-514.
118. Nozaki T, Sugiyama S, Sugamura K, Ohba K, Matsuzawa Y, Konishi M, Matsubara J, Akiyama E, Sumida H, Matsui K, Jinnouchi H, Ogawa H. Prognostic value of endothelial microparticles in patients with heart failure. Eur J Heart Fail. 2010;11:1223-1228.
119. Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci. 2005;1051:743-778. (Pubitemid 41362801)
120. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Froland SS, Aukrust P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;2: 220-225. (Pubitemid 32095406)
121. Aukrust P, Yndestad A, Ueland T, Damas JK, Froland SS, Gullestad L. The role of intravenous immunoglobulin in the treatment of chronic heart failure. Int J Cardiol. 2006;1:40-45. (Pubitemid 44247197)
122. Brunetti L, DeSantis ER. Treatment of viral myocarditis caused by coxsackievirus B. Am J Health Syst Pharm. 2008;2:132-137.
123. Dennert R, Velthuis S, Schalla S, Eurlings L, van Suylen RJ, van PP, Tervaert JW, Wolffs P, Goossens VJ, Bruggeman C, Waltenberger J, Crijns HJ, Heymans S. Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antivir Ther. 2010;2:193-201.
124. Kishimoto C, Takada H, Kawamata H, Umatake M, Ochiai H. Immunoglobulin treatment prevents congestive heart failure in murine encephalomyocarditis viral myocarditis associated with reduction of inflammatory cytokines. J Pharmacol Exp Ther. 2001;2:645-651. (Pubitemid 32979678)
125. Olivieri BP, Vasconcellos R, Nobrega A, Minoprio P, Kaveri SV, raujo-Jorge TC. Intravenous immunoglobulin increases survival time in the acute phase of experimental Chagas disease. Parasite Immunol. 2010;6:464-469.
126. Pisoni CN, Brucato A, Ruffatti A, Espinosa G, Cervera R, Belmonte-Serrano M, Sanchez-Roman J, Garcia-Hernandez FG, Tincani A, Bertero MT, Doria A, Hughes GR, Khamashta MA. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum. 2010;4: 1147-1152.
127. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med. 1997;9:721-730. (Pubitemid 27184044)
128. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;10:747-755.
129. Damas JK, Gullestad L, Aass H, Simonsen S, Fjeld JG, Wikeby L, Ueland T, Eiken HG, Froland SS, Aukrust P. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure-modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol. 2001;1:187-193. (Pubitemid 32613849)
130. Larsson L, Mobini R, Aukrust P, Gullestad L, Wallukat G, Waagstein F, Fu M. Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody. Autoimmunity. 2004;6-7: 489-493. (Pubitemid 40123419)
131. Krause I, Blank M, Kopolovic J, Afek A, Goldberg I, Tomer Y, Shoenfeld Y. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin. J Rheumatol. 1995;6:1068-1074.
132. Levy Y, Sherer Y, Ahmed A, Fabbrizzi F, Terryberry J, Shen GQ, Peter JB, Shoenfeld Y. Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment. Nat Immun. 1998;5-6:207-214.
133. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol. 1988;2:311-316.
134. Rossi F, Jayne DR, Lockwood CM, Kazatchkine MD. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol. 1991;2: 298-303.
135. Lemieux R, Bazin R, Neron S. Therapeutic intravenous immunoglobulins. Mol Immunol. 2005;7:839-848. (Pubitemid 40489033)
136. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a
137. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;7354:110-113.
138. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;5:328-343.